APOH and autoimmune polyendocrinopathy: There are many difficulties in studying anti-B2GPI antibodies and one of the key remaining questions is how to identify patients with the highest risk of thrombosis or obstetric morbidity—i.e., why do some patients with anti-B2GPI develop APS and others do not?